SCHEMBL4712950

SCHEMBL4712950

O=Cc1ccc(-c2cccc(-c3nc4c(Cl)cccc4[nH]3)c2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
POLB P06746 3/20 0.44
KDM4E B2RXH2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MGAM O43451 5/20 0.43
GAA P10253 5/20 0.43
SI P14410 5/20 0.43
MGAM2 Q2M2H8 5/20 0.43
MAPT P10636 1/20 0.43
PARP1 P09874 3/20 0.42
CYP2E1 P05181 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2B6 P20813 1/20 0.41
CYP2C19 P33261 1/20 0.41
ADORA3 P0DMS8 1/20 0.39
ADORA1 P30542 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717701 0.79 MGAM (0.48) MGAMGAASIMGAM2PARP1
SCHEMBL4716304 0.78 GAA (0.47) ALDH1A1KDM4EMGAMGAASI
SCHEMBL14587796 0.76 ADORA3 (0.46) MGAMGAASIMGAM2PARP1
SCHEMBL4715176 0.74 MGAM (0.43) MGAMGAASIMGAM2PARP1
SCHEMBL4717461 0.74 MGAM (0.43) MGAMGAASIMGAM2MAPT
SCHEMBL27961298 0.72 ADORA1 (0.57) ALDH1A1POLBKDM4EMGAMGAA
SCHEMBL4715207 0.72 GAA (0.54) ALDH1A1KDM4EMGAMGAASI
SCHEMBL624327 0.71 ALDH1A1 (0.60) ALDH1A1POLBKDM4ETDP1L3MBTL1
SCHEMBL5666118 0.70 PARP1 (0.43) MGAMGAASIMGAM2PARP1
SCHEMBL1170768 0.70 ADORA1 (0.61) ALDH1A1KDM4EMGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 ALDH1A1 3073/4885POLB 3342/4885KDM4E 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.